reported that YTHDC2 could enhance the translation initiation of IGF1R mRNA to promote radiotherapy resistance in NPC cells.[13] Although m6A alters mRNA stability and translation, rapidly accumulating evidence highlights the significance of crosstalk between this epitranscriptomic modification and histone epigenetic regulation in physio‐pathological cellular processes.[14] Whether histone methylation modulators can be regulated by m6A modification and, if so, what they do and how they act in NPC development and progression remain to be elucidated. The gene discussed is YTHDC2; the disease is nasopharyngeal carcinoma.